The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

Sep. 17, 2019
Applicant:

Shire Human Genetic Therapies, Inc., Lexington, MA (US);

Inventors:

Pericles Calias, Melrose, MA (US);

Jing Pan, Boxborough, MA (US);

Jan Powell, Concord, MA (US);

Lawrence Charnas, Natick, MA (US);

Thomas McCauley, Cambridge, MA (US);

Teresa Leah Wright, Lexington, MA (US);

Richard Pfeifer, North Granby, CT (US);

Zahra Shahrokh, Weston, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/43 (2006.01); A61K 38/47 (2006.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 9/19 (2006.01); C12N 9/24 (2006.01); A61K 9/00 (2006.01); A61K 38/46 (2006.01); C07K 14/65 (2006.01); C12N 9/42 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01);
U.S. Cl.
CPC ...
A61K 38/47 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61K 38/46 (2013.01); A61K 38/465 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); C07K 14/65 (2013.01); C12N 9/2402 (2013.01); C12N 9/2437 (2013.01); C12Y 301/06008 (2013.01); C12Y 301/06013 (2013.01); C12Y 302/0105 (2013.01); C12Y 302/01045 (2013.01); C12Y 302/01046 (2013.01); C12Y 310/01001 (2013.01);
Abstract

The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.


Find Patent Forward Citations

Loading…